19/08/2026
# FDA Philippines Orders Cosmetic Recalls After Tretinoin and Hydroquinone Detection
The Philippine Food and Drug Administration has ordered the recall of specific batches of **three locally marketed cosmetic products** after post-market laboratory testing detected **tretinoin and hydroquinone**, substances prohibited for use in cosmetic products under the ASEAN Cosmetic Directive (ACD).
The enforcement action is particularly relevant to cosmetic brand owners, formulators, distributors and contract manufacturers because the affected products were subject to **formal product recall advisories**, rather than simply being identified as unauthorized cosmetics without valid Certificates of Product Notification.
The affected products include a **facial toner**, covered by **FDA Advisory No. 2026-0856, dated 30 July 2026**; a **rejuvenating night cream**, covered by **FDA Advisory No. 2026-0857, date [VERIFY]**; and another **rejuvenating facial toner**, covered by **FDA Advisory No. 2026-0858, dated 30 July 2026**.
For commercial sensitivity, the brand and product trade names have been redacted from this report. Companies requiring the exact affected products and batches should consult the original FDA advisories.
FDA reported that laboratory analysis conducted through its post-marketing surveillance activities identified **tretinoin and hydroquinone** in the affected products. Both substances are prohibited for use in cosmetic products under **Annex II of the ASEAN Cosmetic Directive**.
# # Why this matters under Philippine cosmetic rules
Cosmetic products placed on the Philippine market operate within the ASEAN-harmonized regulatory framework implemented by FDA Philippines.
The agency continues to incorporate amendments adopted by the ASEAN Cosmetic Committee into Philippine requirements. **FDA Circular No. 2026-0001** consolidated amendments to the ASEAN Cosmetic Directive adopted during the 40th to 42nd ASEAN Cosmetic Committee meetings and their related meetings.
The broader regulatory authority of FDA comes from **Republic Act No. 9711, or the Food and Drug Administration Act of 2009**, which strengthened FDA's authority over health products, including cosmetics, and provides the regulatory basis for post-market surveillance and enforcement activities.
The latest recalls reinforce an important compliance principle for Philippine cosmetic businesses:
**A Certificate of Product Notification does not end a company's regulatory responsibility.**
Products already circulating in the market remain subject to FDA sampling, laboratory examination, post-market surveillance and enforcement.
A product whose declared formulation appears compliant may therefore still create regulatory exposure if laboratory testing detects undeclared pharmaceutical ingredients, prohibited substances, contaminants or other ingredients inconsistent with the notified formulation.
# # What brand owners need to do
* **Recheck formulations against the latest ACD annexes.** Do not rely exclusively on ingredient restrictions that were reviewed when the product was originally developed or notified.
* **Review Certificates of Analysis and raw-material specifications.** Particular attention should be given to products marketed for whitening, rejuvenating, brightening, acne control, peeling or intensive skin resurfacing.
* **Strengthen supplier qualification.** Require adequate documentation for high-risk raw materials and investigate inconsistencies between specifications, certificates and actual material characteristics.
* **Consider appropriate finished-product verification.** Ingredient declarations alone cannot demonstrate that an undeclared prohibited substance is absent from the finished cosmetic.
* **Maintain an updated Product Information File (PIF).** FDA Circular No. 2023-0001 establishes updated Philippine requirements for cosmetic PIFs. Formula information, raw-material specifications, manufacturing information, safety substantiation and supporting records should remain readily available.
* **Maintain effective batch traceability.** Companies should be capable of identifying which raw-material lots entered each production batch and where affected finished-product batches were distributed.
* **Maintain a documented recall procedure.** Manufacturers, traders and distributors should be prepared to quarantine and retrieve affected stocks quickly if FDA orders corrective action.
# # Deadlines and affected stocks
The FDA recall advisories apply to specifically identified affected stocks or batches. No general industry-wide grace period allowing the continued use of tretinoin or hydroquinone in cosmetics was identified in the reviewed recall materials.
Companies should therefore **not interpret the recall as establishing a transition period for formulations containing these substances**.
The enforcement action also comes amid continued scrutiny of problematic skin-lightening cosmetics in the Philippine market. In August 2026, the **EcoWaste Coalition** reported detecting mercury in multiple skin-lightening products obtained from the market. The organization reported that some of its findings had been submitted to FDA and had contributed to public health warnings against certain products.
For legitimate cosmetic businesses, these developments highlight the growing importance of compliance beyond obtaining an LTO and submitting a CPN. **Supplier controls, formulation verification, PIF maintenance, traceability and post-market monitoring are increasingly important parts of regulatory risk management.**
Brand owners should consult **FDA Philippines at fda.gov.ph** for the complete text of FDA Advisories Nos. **2026-0856, 2026-0857 and 2026-0858**, including the identities of the recalled products and affected batches.
Businesses uncertain whether their formulations, supplier documentation, PIFs or existing product notifications comply with current FDA and ASEAN Cosmetic Directive requirements may consider obtaining professional regulatory compliance assistance before an issue reaches the post-market enforcement stage.
# # Sources
* FDA Philippines — FDA Advisory No. 2026-0856, Product Recall of Affected Stocks of a Facial Toner Due to the Presence of Tretinoin and Hydroquinone
* FDA Philippines — FDA Advisory No. 2026-0857, Product Recall of Affected Stocks of a Rejuvenating Night Cream Due to the Presence of Tretinoin and Hydroquinone
* FDA Philippines — FDA Advisory No. 2026-0858, Product Recall of Affected Stocks of a Rejuvenating Facial Toner Due to the Presence of Tretinoin and Hydroquinone
* FDA Philippines — FDA Circular No. 2026-0001, Consolidated Amendments to the ASEAN Cosmetic Directive
* FDA Philippines — FDA Circular No. 2023-0001, Updated Guidelines on Product Information File (PIF) for Cosmetic Products
* EcoWaste Coalition / Pressenza — August 2026 report concerning mercury-containing skin-lightening cosmetics
